Mayo Clinic | Strategic Alliance Partners

May 28, 2024

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.

May 23, 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

May 13, 2024

Melanoma is often detected later in people with darker skin complexions and the consequences can be devastating, a Mayo Clinic study reveals.

May 03, 2024

Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.

April 24, 2024

Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.

April 11, 2024

Matthew P. Goetz, MD, discusses pharmacokinetic data for neoadjuvant (Z)-endoxifen in estrogen receptor–positive, HER2-negative breast cancer.

April 06, 2024

Saad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.

March 28, 2024

Ricardo D. Parrondo, MD, discusses the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

March 28, 2024

Saad J. Kenderian, MB, CHB, discusses ongoing research taking place to potentially move liso-cel into earlier lines of therapy for patients with CLL.

March 25, 2024

Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma.

March 20, 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the unique potential advantages of the radiotherapeutic iopofosine I 131 in Waldenström macroglobulinemia.

March 15, 2024

Saad J. Kenderian, MD, CHB, discusses the FDA approval of lisocabtagene maraleucel for chronic lymphocytic leukemia or small lymphocytic lymphoma.

March 14, 2024

Paul D. Brown, MD, gives a history of prophylactic cranial irradiation in small cell lung cancer and describes its standing in the treatment paradigm.

March 13, 2024

We consider artificial intelligence hype vs reality, focusing on predictive modeling to answer medical questions about diagnosis, treatment choice, etc.

March 08, 2024

Sikander Ailawadhi, MD, discusses early efficacy and safety data for iopofosine I 131 monotherapy in Waldenström macroglobulinemia.

March 06, 2024

Dan S. Childs, MD, discusses treatment with olaparib and abiraterone in metastatic castration-resistant prostate cancer.

March 01, 2024

Dan S. Childs, MD, discusses the evolution of the treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

March 01, 2024

Eric S. Winer, MD, discusses the mechanism of action of emavusertib and preliminary findings from the TakeAim Leukemia trial in acute myeloid leukemia.

February 26, 2024

Jacob Shreve, MD, MS, highlights the intersection between artificial intelligence and personalized medicine, as well as its potential utility in gastrointestinal cancers.

February 22, 2024

Muhamad Alhaj Moustafa, MD, MS, discusses standard treatments for transplant-eligible and transplant-ineligible patients with mantle cell lymphoma.